Elite Pharmaceuticals’ SequestOx™ Study Results Expected in July
May 25, 2017 11:04 am UTC| Business
NORTHVALE, N.J., May 25, 2017 -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), today announced that top-line results for its reformulated SequestOx™ study are expected in July 2017. Patient...
Elite Pharmaceuticals’ SequestOx™ Study Results Expected in July
May 25, 2017 11:04 am UTC| Business
NORTHVALE, N.J., May 25, 2017 -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), today announced that top-line results for its reformulated SequestOx™ study are expected in July 2017. Patient...
May 25, 2017 11:04 am UTC| Business
Earnings per diluted Class A Nonvoting Common Share were $0.43 in the third quarter of fiscal 2017 compared to $0.42 in the same quarter of the prior year.Organic revenue declined 1.9 percent for the quarter ended April...
May 25, 2017 11:04 am UTC| Business
Earnings per diluted Class A Nonvoting Common Share were $0.43 in the third quarter of fiscal 2017 compared to $0.42 in the same quarter of the prior year.Organic revenue declined 1.9 percent for the quarter ended April...
May 25, 2017 11:04 am UTC| Business
Earnings per diluted Class A Nonvoting Common Share were $0.43 in the third quarter of fiscal 2017 compared to $0.42 in the same quarter of the prior year.Organic revenue declined 1.9 percent for the quarter ended April...
May 25, 2017 11:04 am UTC| Business
Earnings per diluted Class A Nonvoting Common Share were $0.43 in the third quarter of fiscal 2017 compared to $0.42 in the same quarter of the prior year.Organic revenue declined 1.9 percent for the quarter ended April...
May 25, 2017 11:04 am UTC| Business
Earnings per diluted Class A Nonvoting Common Share were $0.43 in the third quarter of fiscal 2017 compared to $0.42 in the same quarter of the prior year.Organic revenue declined 1.9 percent for the quarter ended April...